Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells
Related Experiment Video
Updated: Oct 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
1Department of Medical Oncology, Newcastle Mater Misericordiae Hospital, Newcastle, NSW, Australia, 2298. mdspa8@cc.newcastle.edu.au
Abstract:
In this study, the downstream effects of thymidylate synthase (TS) inhibition in L1210 (p53 mutant) and HL60 (p53 null) leukaemia cells were investigated. TS inhibition was induced by the specific TS inhibitor Thymitaq. Within 24 h, TS inhibition resulted in S-phase cell cycle arrest in both cell lines and subsequent apoptotic cell death as characterized by nuclear condensation, DNA fragmentation and the formation of apoptotic bodies. A biphasic hyper/hypopolarization of the mitochondrial membrane potential (delta psi m) was also observed. The mitochondrial permeability transition inhibitor, cyclosporin A, increased the baseline level of delta psi m in L1210 cells. However, along with bongkrekic acid, it did not influence the changes in delta psi m induced by TS inhibition in either cell line. In both cell lines the broad spectrum caspase inhibitor, zVAD.fmk as a single agent, induced a significant downward shift in the baseline of delta psi m. However, only in HL60 cells was this accompanied by a slight increase in cytotoxicity. In L1210 cells zVAD.fmk inhibited DNA fragmentation induced by Thymitaq but did not influence other cell cycle events (S-phase arrest) or the biphasic mitochondrial alterations, indicating caspase involvement downstream but not upstream of the mitochondria following TS inhibition. In HL60 cells, zVAD.fmk reduced the hyperpolarization of delta psi m observed with Thymitaq alone and failed to inhibit the increase in the sub-G1 population induced by Thymitaq. Moreover, zVAD.fmk significantly increased the cell death response of these cells following TS inhibition. In conclusion, cell death induced by TS inhibition is mediated via the apoptotic pathway which clearly involves biphasic alterations in delta psi m. In L1210 cells, but not in HL60 cells, caspases function as the final executioner of apoptosis.
Insights
Thymidylate synthase (TS) inhibition triggers apoptosis and mitochondrial changes in leukemia cells. Caspase involvement in cell death pathways differs between L1210 and HL60 cell lines following TS inhibition.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Thymidylate synthase (TS) is a critical enzyme in DNA synthesis.
- Inhibition of TS is a common strategy in cancer chemotherapy.
- Understanding downstream effects of TS inhibition is crucial for optimizing cancer treatment.
Purpose of the Study:
- To investigate the downstream effects of TS inhibition on L1210 and HL60 leukemia cells.
- To elucidate the role of mitochondrial membrane potential and caspases in TS inhibition-induced cell death.
Main Methods:
- TS inhibition induced using Thymitaq.
- Cell cycle analysis (S-phase arrest).
- Apoptosis assessment (nuclear condensation, DNA fragmentation, apoptotic bodies).
- Mitochondrial membrane potential (Δψm) analysis.
- Pharmacological inhibition of caspases (zVAD.fmk) and mitochondrial permeability transition (cyclosporin A, bongkrekic acid).
Main Results:
- TS inhibition caused S-phase arrest and apoptosis in both cell lines within 24 hours.
- A biphasic alteration in mitochondrial membrane potential (Δψm) was observed.
- Caspase inhibition (zVAD.fmk) affected Δψm and apoptosis differently in L1210 and HL60 cells.
- Caspases acted as downstream effectors of apoptosis in L1210 cells but not in HL60 cells.
Conclusions:
- TS inhibition induces apoptosis via a pathway involving biphasic Δψm alterations.
- Caspase-dependent apoptosis occurs downstream of mitochondrial events in L1210 cells.
- HL60 cells exhibit caspase-independent or alternative cell death mechanisms following TS inhibition.
Related Concept Videos
Antiprotozoal Agents
The Intrinsic Apoptotic Pathway
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
